Skip to main content

Eloxx Pharmaceuticals, Inc. (ELOX)

NASDAQ: ELOX · IEX Real-Time Price · USD
1.53 -0.03 (-1.92%)
Oct 15, 2021 4:00 PM EDT - Market closed
Market Cap131.89M
Revenue (ttm)n/a
Net Income (ttm)-57.50M
Shares Out66.39M
EPS (ttm)-1.23
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume142,962
Open1.57
Previous Close1.56
Day's Range1.52 - 1.57
52-Week Range1.18 - 6.77
Beta2.22
AnalystsBuy
Price Target3.77 (+146.4%)
Est. Earnings DateNov 4, 2021

About ELOX

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial that focuses on the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.

IndustryPharmaceuticals
Founded2013
CEORobert Ward
Employees25
Stock ExchangeNASDAQ
Ticker SymbolELOX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for ELOX stock is "Buy." The 12-month stock price forecast is 3.77, which is an increase of 146.41% from the latest price.

Price Target
$3.77
(146.41% upside)
Analyst Consensus: Buy

News

Eloxx Pharmaceuticals to Host Investor and Analyst Call and Webcast on Cystic Fibrosis Programs

Globally renowned CF Expert, Dr. Eitan Kerem will provide key insights

1 week ago - GlobeNewsWire

Eloxx Pharmaceuticals Secures Debt Facility of Up to $30 Million from Hercules Capital

WATERTOWN, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), today announced that the company has entered into a debt facility of up to $30.0 million with Hercules Cap...

1 week ago - GlobeNewsWire

Eloxx Stock Moves Higher On Fast Track Tag For Cystic Fibrosis Candidate

The FDA has granted Fast Track designation Eloxx Pharmaceuticals Inc's (NASDAQ: ELOX) ELX-02, a drug candidate intended to treat cystic fibrosis patients with nonsense mutations. ELX-02 is currently in ...

1 month ago - Benzinga

New Strong Sell Stocks for August 24th

BGS, FTHM, NTLA, LEVL, and ELOX have been added to the Zacks Rank #5 (Strong Sell) List on August 24, 2021

Other symbols:BGSFTHMLEVLNTLA
1 month ago - Zacks Investment Research

Eloxx Pharmaceuticals Reports Second Quarter 2021 Financial and Operating Results and Provides Business Update

Added Additional Treatment Arm and Provided Enrollment Update for Ongoing ELX-02 Phase 2 Clinical Trials for Cystic Fibrosis (CF)

2 months ago - GlobeNewsWire

Hemogenyx Pharmaceuticals PLC Announces Appointment of Business Advisor & Board Observer

Dr Alan E. Walts joins Hemogenyx Pharmaceuticals team; renowned business leader brings industry experience in corporate and private venture capital, business development, R&D and general management. LON...

2 months ago - Accesswire

Eloxx Pharmaceuticals Provides Enrollment Update for Ongoing Phase 2 Clinical Studies for Cystic Fibrosis

Data Readout for First Four Treatment Arms Expected in the Fourth Quarter of 2021 Data Readout for First Four Treatment Arms Expected in the Fourth Quarter of 2021

3 months ago - GlobeNewsWire

7 Reddit Penny Stocks to Watch For the Long Weekend

With July 4th on the way, which penny stocks are you watching right now? The post 7 Reddit Penny Stocks to Watch For the Long Weekend appeared first on Penny Stocks to Buy, Picks, News and Information |...

Other symbols:CPGGLBSMARKRAVE
3 months ago - PennyStocks

Are Options Traders Betting on a Big Move in Eloxx Pharmaceuticals (ELOX) Stock?

Investors need to pay close attention to Eloxx Pharmaceuticals (ELOX) stock based on the movements in the options market lately.

4 months ago - Zacks Investment Research

Is the Options Market Predicting a Spike in Eloxx (ELOX) Stock?

Investors need to pay close attention to Eloxx (ELOX) stock based on the movements in the options market lately.

4 months ago - Zacks Investment Research

Eloxx Pharmaceuticals, Inc. Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwrit...

WALTHAM, Mass., May 18, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (the “Company”) (Nasdaq: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced the c...

4 months ago - GlobeNewsWire

Why Bionano Genomics, CorMedix and Eloxx Are Moving Friday

Bionano Genomics, Inc. (NASDAQ: BNGO), CorMedix Inc. (NASDAQ: CRMD) and Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) are among the health care movers Friday. Bionano Moves On Q1 Results: Bionano reported ...

Other symbols:BNGOCRMD
5 months ago - Benzinga

Eloxx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock

WALTHAM, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (the “Company”) (Nasdaq: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced the p...

5 months ago - GlobeNewsWire

Eloxx Pharmaceuticals Reports First Quarter 2021 Financial and Operating Results and Provides Business Update

Acquisition of Zikani Therapeutics, Ribosomal Modulation Company; Combined Company Advancing Ribosomal RNA-Targeted Genetic Therapies

5 months ago - GlobeNewsWire

Eloxx Pharmaceuticals Adds Additional Treatment Arm to Ongoing Phase 2 Clinical Studies for Cystic Fibrosis

Fifth Treatment Arm to Evaluate Safety of ELX-02 in Combination with Kalydeco (ivacaftor)

5 months ago - GlobeNewsWire

Eloxx Pharmaceuticals (ELOX) Is in Oversold Territory: What's Next?

Eloxx Pharmaceuticals (ELOX) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

5 months ago - Zacks Investment Research

Eloxx Stock is Trading Higher After Zikani Therapeutics Acquisition

Eloxx Pharmaceuticals Inc (NASDAQ: ELOX) has acquired Zikani Therapeutics Inc in an all-stock transaction. The new entity will focus on ribosomal RNA-targeted therapies for the treatment of rare disease...

6 months ago - Benzinga

Eloxx Pharmaceuticals Acquires Zikani Therapeutics

Combined Company to be Leader in Ribosomal RNA-Targeted Genetic Therapy Bringing Together Complementary Platforms

6 months ago - GlobeNewsWire

Eloxx Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Operating Results and Provides Business...

We expect to report top line data from our Phase 2 cystic fibrosis clinical trials in the first half of this year

7 months ago - GlobeNewsWire

Eloxx Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Business Update on Ma...

Company management to host a webcast and conference call to provide a business update and review financial results at 4:30 p.m. ET Company management to host a webcast and conference call to provide a b...

7 months ago - GlobeNewsWire

Eloxx Announces Publication of Scientific Manuscript on ELX-02 in the Journal of Clinical Pharmacology in Drug Develo...

Publication titled: “ A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of ELX-02 in Healthy Subjects”

8 months ago - GlobeNewsWire

Eloxx Announces Publication of Scientific Manuscript on ELX-02 in the Journal of Clinical Pharmacology

Publication titled: “Phase 1 Renal Impairment Trial Results Enable Targeted Individualized Dosing of ELX-02 in Nephropathic Cystinosis Patients” Publication titled: “Phase 1 Renal Impairment Trial Resul...

8 months ago - GlobeNewsWire

Eloxx Pharmaceuticals Announces Cystic Fibrosis Foundation (CF Foundation) To Provide Increased Funding and Support f...

The CF Foundation's partial funding of the U.S. trial has been extended to partial funding of the global clinical trial program which includes Europe and Israel

9 months ago - GlobeNewsWire

Eloxx Pharmaceuticals (ELOX) in Focus: Stock Moves 6.9% Higher

Eloxx Pharmaceuticals (ELOX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

10 months ago - Zacks Investment Research

Eloxx Pharmaceuticals to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

WALTHAM, Mass., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics ...

10 months ago - GlobeNewsWire